GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (STU:29Y) » Definitions » EV-to-EBIT

Spexis AG (STU:29Y) EV-to-EBIT : -0.89 (As of May. 26, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Spexis AG EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Spexis AG's Enterprise Value is €11.06 Mil. Spexis AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-12.41 Mil. Therefore, Spexis AG's EV-to-EBIT for today is -0.89.

The historical rank and industry rank for Spexis AG's EV-to-EBIT or its related term are showing as below:

STU:29Y' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.36   Med: 0.77   Max: 2.18
Current: -0.89

During the past 10 years, the highest EV-to-EBIT of Spexis AG was 2.18. The lowest was -10.36. And the median was 0.77.

STU:29Y's EV-to-EBIT is ranked worse than
100% of 426 companies
in the Biotechnology industry
Industry Median: 10.295 vs STU:29Y: -0.89

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Spexis AG's Enterprise Value for the quarter that ended in Jun. 2023 was €550.22 Mil. Spexis AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-12.41 Mil. Spexis AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -2.25%.


Spexis AG EV-to-EBIT Historical Data

The historical data trend for Spexis AG's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG EV-to-EBIT Chart

Spexis AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.57 -0.29 -82.37 -6.60 -1.30

Spexis AG Semi-Annual Data
Dec13 Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -6.60 - -1.30 -

Competitive Comparison of Spexis AG's EV-to-EBIT

For the Biotechnology subindustry, Spexis AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spexis AG's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spexis AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Spexis AG's EV-to-EBIT falls into.



Spexis AG EV-to-EBIT Calculation

Spexis AG's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=11.063/-12.405
=-0.89

Spexis AG's current Enterprise Value is €11.06 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Spexis AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-12.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spexis AG  (STU:29Y) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Spexis AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=-12.405/550.218064
=-2.25 %

Spexis AG's Enterprise Value for the quarter that ended in Jun. 2023 was €550.22 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Spexis AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was €-12.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spexis AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Spexis AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Spexis AG (STU:29Y) Business Description

Traded in Other Exchanges
Address
Hegenheimermattweg 125, Allschwil, CHE, CH-4123
Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (STU:29Y) Headlines

No Headlines